Document is current
Any future updates will be listed below
-
Authors
Nakamura, Kosei https://orcid.org/0009-0002-6429-0628
Kuroha, Yasuko
Hatakeyama, Masahiro https://orcid.org/0000-0003-0426-8568
Kimura, Atsushi Michael
Nakamura, Yukimi https://orcid.org/0000-0001-5983-1261
Murakami, Yoshihiro
Watanabe, Masaki https://orcid.org/0000-0002-5236-7563
Igarashi, Hironaka https://orcid.org/0000-0003-1663-5564
Takahashi, Tetsuya https://orcid.org/0000-0002-3934-0219
Shimada, Hitoshi https://orcid.org/0000-0002-7139-7178
-
Funding
Funding for this research was provided by:
JSPS KAKENHI Grant-in-Aid for Scientific Research (JP23H02825)
JSPS KAKENHI Grant-in-Aid for Scientific Research (JP18K07543)
JST FOREST Program (JPMJFR220R, Japan)
the Japanese Society of Neurology Novartis Pharma Grants for Basic Research 2022
Splink Co., Ltd.
APRINOIA Therapeutics Co., Ltd.
- License Information
-
More Information
Article History
Received: 5 July 2023
Accepted: 5 December 2023
First Online: 12 December 2023
Declarations
:
: The manuscript does not contain clinical studies or patient data. The PET study conducted for the present report was approved by the Niigata University Certified Review Board (UMIN 000050731). Written informed consent was obtained from the patient.
: Written informed consent was obtained from the patient’s next of kin for publication of this case report.
: Hitoshi Shimada holds patents on compounds related to the present report (JP 5422782/EP 12 884 742.3/CA2894994/HK1208672), and received honoraria for lectures from Eizai Co., Ltd., consultant fee from Splink Co., Ltd., and research fundings from Splink Co., Ltd. and Novartis Pharmaceutical Co., Ltd. All other authors declare that they have no conflict of interest.
